Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02225132|
Recruitment Status : Completed
First Posted : August 26, 2014
Results First Posted : August 6, 2019
Last Update Posted : August 6, 2019
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
- Sickle cell disease (SCD) is a blood disease. The drug hydroxyurea (HU) is approved to prevent pain crises in people with SCD. Researchers want to see how higher doses of HU affect the blood. This will help them learn about the right dosage of HU to give to people with SCD.
- To improve hydroxyurea dosing in people with SCD.
- People age 15 or older with homozygous SCD (HbSS).
- Participants will be screened with medical history, physical exam, medication review, and blood and urine tests.
- Participants will be in the study for about 15 months.
- First 3 months: monthly study visits with blood and urine tests.
- After 3 months: participants will take HU as a capsule by mouth. If you are already taking HU, your dose will be increased.
- Within a month of starting or increasing HU: participants will keep a daily pain diary for 2 weeks. They will have an echocardiogram (ultrasound) of the heart, a 6-minute walk test. They will complete a quality-of-life questionnaire.
- Participants will visit every month until they reach their highest tolerated dose of HU. They may need to come as often as every week sometimes to closely monitor their blood counts. Then they will alternate a phone call one month and a visit the next. At the visits, participants will bring their pill bottle, answer questions about side effects, and have blood tests.
- Every 2 months, participants will have a medical history, physical exam, and blood tests.
- Every 4 months, participants will have blood and urine tests. They will also complete another 2-week pain diary and quality-of-life questionnaire.
- About 12 months after starting or increasing HU, participants will have blood tests, an echocardiogram, and a 6-minute walk test.
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease||Drug: Hydroxyurea||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of Computerized Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in Subjects With Sickle Cell Disease|
|Study Start Date :||August 23, 2014|
|Actual Primary Completion Date :||May 24, 2018|
|Actual Study Completion Date :||May 24, 2018|
This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.
The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.
- Fetal Hemoglobin Level [ Time Frame: Baseline ]Mean fetal hemoglobin calculated to indicate effectiveness of hydroxyurea dose
- Fetal Hemoglobin Level [ Time Frame: 12 months ]Mean fetal hemoglobin calculated to indicate effectiveness of hydroxyurea dose
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||15 Years to 99 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age greater than or equal to 15 years
- Homozygous sickle cell disease (HbSS)
- Patients with recent transfusion must have HbA <15% prior to enrollment
- ANC greater than or equal to 2,000/microL, platelets greater than or equal to150,000/microL, Hb > 5.4g/dL, and ARC greater than or equal to100,000/microL (unless the Hb is > 8g/dL) at baseline
- Patients on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers should be on a stable dose for 2 weeks prior to initiating or adjusting HU
- Pregnant or lactating women or patients planning to get pregnant during the study period
- Patients unwilling to use two forms of contraception throughout the period of HU administration
- Patients receiving chronic transfusion therapy
- Patients receiving a HU dose of greater than or equal to 20 mg/kg/day
- Patients with history of allergy or intolerance to HU judged by the investigator to be prohibitive against restarting HU
6 Patients with end stage renal disease defined as GFR <10mL/min/1.73m(2)
7. Patients being treated with antiretroviral agents (such as didanosine and stavudine) because of a higher risk for potentially fatal pancreatitis, hepatic failure, hepatitis, and severe peripheral neuropathy when co-administered with hydroxyurea.
8. Participation on any other chronic investigative treatment studies
9. Unable to understand the investigational nature of the study or give informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02225132
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Courtney D Fitzhugh, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|
Documents provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
|Responsible Party:||National Heart, Lung, and Blood Institute (NHLBI)|
|Other Study ID Numbers:||
|First Posted:||August 26, 2014 Key Record Dates|
|Results First Posted:||August 6, 2019|
|Last Update Posted:||August 6, 2019|
|Last Verified:||April 25, 2019|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Sickle Cell Disease
Fetal Hemoglobin Induction
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors